AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

THE PEDIATRIC GAP.

The New Yorker

| January 10, 2005 | Groopman, Jerome | COPYRIGHT 2003 All rights reserved. Reproduced by permission of The Condé Nast Publications Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Not long ago, a three-year-old boy fell off a jungle gym in Boston and lacerated his cheek. His parents rushed him to the emergency room of a nearby hospital. A nurse restrained the screaming boy while a surgeon cleaned his cheek and injected it with a small dose of bupivacaine, a local anesthetic that is widely used in adults. When the surgeon began to suture the wound, the child had a seizure and his blood pressure suddenly dropped; he was on the verge of going into shock. He was transferred to the intensive-care unit, where doctors tried to account for his symptoms. A cat scan taken to see if the fall had caused cerebral hemorrhage showed no evidence of brain damage.

Maureen Strafford, a pediatric anesthesiologist and cardiologist, was paged to assist, and she found that the level of bupivacaine in the boy's blood was perilously high. The boy was intubated and placed on a respirator. He spent several days in intensive care before recovering from the overdose.

The package insert for bupivacaine does not provide specific dosing information for children; the E.R. surgeon had adjusted for the boy's weight by "dosing down" from the amount recommended for adults. But such extrapolations cannot account for the differences in the biology of children. Even growing teen-agers who weigh as much as adults tend to absorb and metabolize medicine more quickly than adults, since organs that break down drugs, such as the liver, or excrete chemicals, such as the kidneys, take years to mature. The rate of blood flow to the skin and lungs is also higher in children, so topical or inhaled agents may be more rapidly absorbed.

Strafford told me that the surgeon's decision to improvise with bupivacaine was not unusual. Although the Food and Drug Administration has long required that medications be screened for safety in adults, approximately seventy-five per cent of drugs approved for use in the United States have never been subjected to comprehensive pediatric studies. A physician, however, is allowed to use any F.D.A.-approved drug in whatever way he deems beneficial, and he isn't required to inform parents if it hasn't been specifically tested on children. There is no single official repository of information about how to calibrate drug dosages for children. Since pharmaceutical companies rarely collect data about the effects of their drugs on minors, there is scant information about pediatric dosing in the Physicians' Desk Reference, a compendium of guidelines and warnings supplied by drug companies; pediatric handbooks are published by private companies, but they are not comprehensive and their data are not obtained through a consistent methodology. In the absence of reliable information, doctors are frequently forced to engage in guesswork when administering drugs. Speaking of the three-year-old boy, Strafford said, "This is a perfect example of what can happen to a healthy kid."

I recently spoke with Ellis Neufeld, a pediatric hematologist at Children's Hospital Boston, who has begun to document the different ways children react to Lovenox, an anticoagulant that has been safely used in adults. A teen-ager at the hospital, he said, had recently developed a severe brain hemorrhage after taking the drug; emergency neurosurgery was required to save his life. This spring, Neufeld completed a preliminary study of thirty children who had been placed on closely monitored regimens of Lovenox. The findings helped him formulate a set of target doses in pediatric patients, adjusting for variables such as kidney function. (In very young children, the renal system is not fully developed.) His results will be ready for publication in several months. In Neufeld's view, such a study should have been required by the F.D.A. before Lovenox was approved for use in children. "The package insert from the drug company does not provide a doctor with what he needs to know," he said. Under the rubric "Pediatric Use," the insert merely states, "Safety and effectiveness of Lovenox Injection in pediatric patients have not been established."

Children with certain illnesses can be especially sensitive to the side effects of a drug. For example, infants with meningitis are much more likely than adults to react poorly to chloramphenicol, an antibiotic that is a…

Related articles from newspapers, magazines, journals, and more
Lovenox(R) Cleared By U.S. FDA to Prevent Blood Clots Following Hip-Replacement...
Press release article from: PR Newswire February 4, 1998 700+ words
...NYSE: RP), announced today that Lovenox(R) (enoxaparin sodium) Injection...following hip-replacement surgery. Lovenox is already indicated for the prevention...by the FDA permits the at-home use of Lovenox for up to three weeks following hip...
Studies show Lovenox as an effective treatment of acute coronary syndromes.
Newspaper article from: Health & Medicine Week August 2, 2004 700+ words
...randomized clinical studies confirm that Lovenox (enoxaparin sodium injection) is an...patients with NSTE ACS showed that overall, Lovenox is superior to unfractionated heparin...prospective, randomized, open-label study of Lovenox versus UFH in more than 10,000 high...
New Data Confirm Lovenox(R) is an Effective Antithrombotic for Treatment of...
Press release article from: PR Newswire July 7, 2004 700+ words
...randomized clinical studies confirm that Lovenox(R) (enoxaparin sodium injection...patients with NSTE ACS showed that overall, Lovenox(R) is superior to unfractionated heparin...prospective, randomized, open-label study of Lovenox(R) versus UFH in more than 10,000...
Lovenox(R) More Effective Than Ximelagatran in Reducing Life-Threatening Blood...
Press release article from: PR Newswire December 10, 2001 700+ words
...Aventis S.A. , today announced that Lovenox (enoxaparin sodium) Injection was found...ximelagataran administered orally (24 mg) or Lovenox injection (30mg), given twice a day...reduction in VTE in patients treated with Lovenox compared to patients treated with ximelagatran...
New Lovenox(R) Data to Be Presented at American Society of Hematology Meeting.
Press release article from: PR Newswire December 5, 2002 700+ words
...supporting the efficacy and safety of Lovenox(R) (enoxaparin sodium injection...patients with acute hip fracture receiving Lovenox(R) for thromboprophylaxis (reduction...receiving UFH. Another study, evaluating Lovenox(R) for at-home treatment of DVT...
ASSENT-3+ Shows Promising Results for LOVENOX(R) in Acute Myocardial Infarction.
Press release article from: PR Newswire November 20, 2002 700+ words
...TNKase(TM) (tenecteplase, TNK) with LOVENOX(R) (enoxaparin sodium) Injection...Pre-hospital thrombolysis with LOVENOX(R) plus TNK or UFH plus TNK reduces...point(1) rates were 14.2% for LOVENOX(R) plus TNK vs. 17.4% for UFH plus...
Aventis to Move Forward With Reissuance Process for Contested Lovenox Patent.
Press release article from: PR Newswire July 27, 2004 700+ words
...389,618 ('618 patent), relating to Lovenox. Aventis remains committed to continuing...seeking to market generic versions of Lovenox by filing Abbreviated New Drug Applications...outcome of the reissuance proceeding. About Lovenox(R) The No. 1-selling low-molecular...
FDA APPROVES LOVENOX(R) (ENOXAPARINSODIUM) FOR USE FOLLOWING KNEE REPLACEMENT...
Press release article from: PR Newswire March 16, 1995 700+ words
...Drug Administration (FDA) has approved Lovenox(R) (enoxaparin sodium) for the prevention...Developed and manufactured by RPR, Lovenox is the first low molecular weight heparin...approved for this usein the United States. Lovenox was introduced in the U.S. in 1993...
Rhone-Poulenc Rorer Seeks FDA Clearance to Market Lovenox for the Treatment of...
Press release article from: PR Newswire March 13, 1997 700+ words
...Food and Drug Administration (FDA) for Lovenox(R) (enoxaparin sodium) Injection...000 deaths each year in the U.S. Lovenox is the only low-molecular-weight heparin...randomized clinical trials that compared Lovenox with standard heparin, the drug most...
Court Confirms PharmaNetics' Allegation That Aventis Has Engaged in False...
Press release article from: Business Wire May 4, 2004 700+ words
...advertising of its second largest drug, Lovenox(R). In addition to claims of false...prevent Aventis from falsely advertising Lovenox. In commenting on the Court's ruling...enjoin Aventis from falsely promoting Lovenox, we are gratified that the Court did...
For more facts and information, see all results
©2010 Gale, a part of Cengage Learning. All rights reserved. About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily